Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study
Isabel Mattig, Berit Zirkelbach, Carina Bonnekoh, Karl Stangl, Gerhard Hindricks, Fabian Knebel, Sima Canaan-Kühl, Sebastian Spethmann · 2026
Read Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study by Isabel Mattig, Berit Zirkelbach, Carina Bonnekoh, Karl Stangl, Gerhard Hindricks, Fabian Knebel, Sima Canaan-Kühl, Sebastian Spethmann (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13195756.txt.
Description
Isabel Mattig and co-authors check how well patients with Fabry disease tolerate a class of heart drugs. Their 2026 study reviews care for close to one hundred patients with this rare storage disease. Heart failure in the disease is treated much as in general care.
One in five patients took the drug class under study. Over a follow-up of about two years, heart and kidney markers stayed stable in that group. Heart scan measures showed no clear pattern, and matched comparisons found no firm gaps. Common side effects were extra urine, low fluid volume, and dizziness. The authors judge the safety profile acceptable in this group. They stop short of claims about benefit, given the small exploratory sample.
Catalog record
| CREATOR | Isabel Mattig, Berit Zirkelbach, Carina Bonnekoh, Karl Stangl, Gerhard Hindricks, Fabian Knebel, Sima Canaan-Kühl, Sebastian Spethmann |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |